HAAS JASON sold 64.2% of their position (7.14K shares) of LIGAND PHARMACEUTICALS INC on the open market
Open‑market sale worth $2.09M — a major position exit. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 8/14/2026ACC: 0002001011-26-000114
-7.14K
Net shares
Net seller
$2.09M
Total sold
1
Open market trades
0B · 1S
3
Total transactions
6.14K acquired · 13.28K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+6.14K
Price / share
$51.56
Trade value
$316.48K
% of position
123.2%
8/12/2026
4.98K→11.12K
Common Stock
Direct
Shares
−7.14K
Price / share
$292.81
Trade value
$2.09M
% of position
64.2%
8/12/2026
11.12K→3.98K
Total
Net shares
−1K
Net value
-$1.77M
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 8/12/2026 | M · Option Exercise | +6.14K | $51.56 | $316.48K | 123.2% | 4.98K | 11.12K |
| Common Stock Direct | 8/12/2026 | S · Sale | −7.14K | $292.81 | $2.09M | 64.2% | 11.12K | 3.98K |
| Total | −1K | -$1.77M | ||||||
Derivative Transactions1
Non-Qualified Stock Option (right to buy)
Direct
Converts to
Common Stock
6.14K shares
Shares
−6.14K
Strike price
51.56
Held after
0.00
Exercisable
—
8/12/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy) Direct | Common Stock6.14K shares | 8/12/2026 | M · Option Exercise | −6.14K | 51.56 | — | 0.00 |